Compare Deere & Company (DE) vs Mesoblast Limited (MESO) Price & Performance

Deere & Company (DE) trades at $656.87, down 3.8% on the day, reflecting near-term pressure amid a broader bearish technical signal. The stock has demonstrated strong earnings momentum, beating estimates in the last three quarters, but faces headwinds from declining revenue and net income margins. Recent news highlights the company's focus on AI-driven agricultural solutions to counter cyclical downturns, while analyst consensus remains divided with a price target of $731.20 suggesting potential upside from current levels.

The outlook for DE is mixed; solid profitability metrics and consistent cash flow generation support the investment case, but cyclical exposure to agriculture equipment demand and elevated valuation ratios pose risks. Earnings growth and successful execution of technology initiatives are key catalysts for outperformance, though macroeconomic volatility could dampen near-term returns.

MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.

The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.